Skip to main content

Table 7 Serum uric acid levels, mg/dL

From: A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjects with hyperuricemia

Group

Baseline

4 weeks

Mean %change

8 weeks

Mean %change

12 weeks

Mean %change

16 weeks

Mean %change

20 weeks

Mean %change

24 weeks

Mean %change

A

9.04 ± 0.64

7.98 ± 0.49

−11.55 ± 4.32

6.63 ± 0.32

−26.37 ± 5.54

4.78 ± 0.60

− 46.80 ± 8.40

3.95 ± 0.59

− 56.16 ± 7.32

3.83 ± 0.52

−57.50 ± 6.16

3.28 ± 0.46

−63.70 ± 4.62

B

8.10 ± 0.67

7.64 ± 0.69

− 5.72 ± 2.15

7.10 ± 0.61

−12.34 ± 2.12

6.95 ± 0.51

−14.07 ± 3.49

6.76 ± 0.37

− 16.25 ± 4.88

6.59 ± 0.27

−18.28 ± 5.47

6.46 ± 0.34

− 19.84 ± 6.43

C

8.54 ± 0.64

8.06 ± 0.66

− 5.70 ± 1.67

7.87 ± 0.70

− 7.87 ± 2.58

6.98 ± 0.70

− 18.32 ± 4.91

6.08 ± 0.55

− 28.67 ± 5.09

5.56 ± 0.41

− 34.70 ± 4.76

5.63 ± 0.37

− 33.88 ± 4.95